Senti Biosciences (SNTI)

• Market cap: $43.4M
• 1 day: -7.26%
• 5 days: -16.16%
• 1 month: -20.19%
• 3 months: 8.5%
• 6 months: -48.29%
• Year to date: -56.43%
• 1 year: -28.76%
• 5 years: -98.34%
• 10 years: -98.34%
• Sector: Healthcare
• Industry: Biotechnology

About: Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.

Employees: 48